IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Animals
Apoptosis
Cell Proliferation
Cytokines
/ antagonists & inhibitors
Drug Resistance, Neoplasm
Hematologic Neoplasms
/ drug therapy
Humans
Isocitrate Dehydrogenase
/ antagonists & inhibitors
Mice
Mice, Inbred NOD
Mice, SCID
Nicotinamide Phosphoribosyltransferase
/ antagonists & inhibitors
Oligopeptides
/ pharmacology
Proteasome Inhibitors
/ pharmacology
RNA, Small Interfering
/ genetics
Sirtuin 3
/ antagonists & inhibitors
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
10 01 2019
10 01 2019
Historique:
received:
16
05
2018
accepted:
16
11
2018
pubmed:
21
11
2018
medline:
21
8
2019
entrez:
21
11
2018
Statut:
ppublish
Résumé
Proteasome inhibitors (PI) are extensively used for the therapy of multiple myeloma (MM) and mantle cell lymphoma. However, patients continuously relapse or are intrinsically resistant to this class of drugs. Here, to identify targets that synergize with PI, we carried out a functional screening in MM cell lines using a short hairpin RNA library against cancer driver genes. Isocitrate dehydrogenase 2 (
Identifiants
pubmed: 30455381
pii: S0006-4971(20)42878-2
doi: 10.1182/blood-2018-05-850826
doi:
Substances chimiques
Cytokines
0
Oligopeptides
0
Proteasome Inhibitors
0
RNA, Small Interfering
0
carfilzomib
72X6E3J5AR
IDH2 protein, human
EC 1.1.1.41
Isocitrate Dehydrogenase
EC 1.1.1.41
Nicotinamide Phosphoribosyltransferase
EC 2.4.2.12
nicotinamide phosphoribosyltransferase, human
EC 2.4.2.12
SIRT3 protein, human
EC 3.5.1.-
Sirtuin 3
EC 3.5.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
156-167Informations de copyright
© 2019 by The American Society of Hematology.